Related Experiment Video
Updated: Jul 16, 2026

Establishment and Evaluation of a Risk Prediction Model for Pathological Escalation of Gastric Low-Grade Intraepithelial Neoplasia
Published on: February 16, 2024
Case Report: Synchronous minute intramucosal Epstein-Barr virus-associated gastric cancer revealed after short-term
Dongqi Wu1, Quan Luo1, Weiming Wang1
1Endoscopy Center, Shaoxing People's Hospital, The First Affiliated Hospital, Shaoxing University, Shaoxing, China.
Abstract:
Epstein-Barr virus-associated gastric cancer (EBVaGC) is a rare subtype, accounting for approximately 8.7% of gastric cancers worldwide. It predominantly affects males and typically presents endoscopically as a superficial depressed lesion or with a submucosal tumor-like appearance. Pathologically, it is characterized by prominent lymphoid stromal infiltration (gastric carcinoma with lymphoid stroma, GCLS). Molecular features include extensive CpG island methylation, PIK3CA mutations, and high PD-L1/PD-L2 expression. We report the case of a 56-year-old patient diagnosed with gastric adenocarcinoma at an outside institution. Upon admission, magnifying endoscopy with narrow-band imaging (ME-NBI) revealed active Helicobacter pylori (HP) infection and a Paris 0-IIc reddish lesion on the posterior wall of the middle gastric body with indistinct margins. The patient underwent a 2-week HP eradication regimen. Subsequent endoscopic submucosal dissection (ESD) revealed two distinct superficial depressed lesions, which were removed en bloc. The lesions measured 15 mm (distal lesion) and 26 mm (proximal lesion), respectively. Postoperative pathology confirmed two independent foci of intramucosal EBVaGC with positive EBER in situ hybridization. The lesions were limited to the mucosa (pTis) without lymphovascular invasion, achieving curative resection (eCura A). At the 6-month follow-up, no recurrence was observed. This case suggests that in the setting of active HP-associated gastritis, EBVaGC may be obscured; Short-term preoperative HP eradication may alleviate background inflammation, potentially improving the detection of minute lesions and the delineation of margins. These findings form a hypothesis that eradication might aid endoscopic assessment, which requires validation in larger cohorts. Under strict risk assessment and margin control, ESD represents a curative modality for early EBVaGC.
Related Concept Videos
Gastritis II: Pathophysiology
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
Peptic Ulcer
Gastritis III: Clinical Manifestations and Management
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
Barrett Esophagus-II: Clinical Manifestations and Management
To diagnose Barrett's esophagus, healthcare providers often recommend an endoscopy for those showing symptoms of acid reflux. The procedure entails...